These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30833449)

  • 1. A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis.
    Coe S; Cossington J; Collett J; Soundy A; Izadi H; Ovington M; Durkin L; Kirsten M; Clegg M; Cavey A; Wade DT; Palace J; DeLuca GC; Chapman K; Harrison JM; Buckingham E; Dawes H
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):507-513. PubMed ID: 30833449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A protocol for a randomised double-blind placebo-controlled feasibility study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue in people with relapsing and remitting multiple sclerosis (RRMS).
    Coe S; Collett J; Izadi H; Wade DT; Clegg M; Harrison JM; Buckingham E; Cavey A; DeLuca GC; Palace J; Dawes H
    Pilot Feasibility Stud; 2018; 4():35. PubMed ID: 29403649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A feasibility study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue and fatigability in people with Parkinson's (pwP).
    Coe S; Andreoli D; George M; Collett J; Reed A; Cossington J; Izadi H; Dixon A; Mansoubi M; Dawes H
    Clin Nutr ESPEN; 2022 Apr; 48():68-73. PubMed ID: 35331536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flavonoid rich dark cocoa may improve fatigue in people with multiple sclerosis, yet has no effect on glycaemic response: An exploratory trial.
    Coe S; Axelsson E; Murphy V; Santos M; Collett J; Clegg M; Izadi H; Harrison JM; Buckingham E; Dawes H
    Clin Nutr ESPEN; 2017 Oct; 21():20-25. PubMed ID: 30014865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study.
    Bertoglio JC; Baumgartner M; Palma R; Ciampi E; Carcamo C; Cáceres DD; Acosta-Jamett G; Hancke JL; Burgos RA
    BMC Neurol; 2016 May; 16():77. PubMed ID: 27215274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effectiveness of a cognitive behavioural therapy (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a multicentre, randomised, open-label, controlled trial versus standard care.
    Gay MC; Cassedanne F; Barbot F; Vaugier I; Thomas S; Manchon E; Bensmail D; Blanchere M; Heinzlef O
    J Neurol Neurosurg Psychiatry; 2024 Jan; 95(2):158-166. PubMed ID: 37648439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Flavonoid Cocoa Supplement Ameliorates Plasma Oxidative Stress and Inflammation Levels While Improving Mobility and Quality of Life in Older Subjects: A Double-Blind Randomized Clinical Trial.
    Munguia L; Rubio-Gayosso I; Ramirez-Sanchez I; Ortiz A; Hidalgo I; Gonzalez C; Meaney E; Villarreal F; Najera N; Ceballos G
    J Gerontol A Biol Sci Med Sci; 2019 Sep; 74(10):1620-1627. PubMed ID: 31056655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pulsed electromagnetic field therapy on fatigue, walking performance, depression, and quality of life in adults with multiple sclerosis: a randomized placebo-controlled trial.
    Granja-Domínguez A; Hochsprung A; Luque-Moreno C; Magni E; Escudero-Uribe S; Heredia-Camacho B; Izquierdo-Ayuso G; Heredia-Rizo AM
    Braz J Phys Ther; 2022; 26(5):100449. PubMed ID: 36283240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
    Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of BEMER magnetic field therapy on the level of fatigue in patients with multiple sclerosis: a randomized, double-blind controlled trial.
    Piatkowski J; Kern S; Ziemssen T
    J Altern Complement Med; 2009 May; 15(5):507-11. PubMed ID: 19422286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body temperature is elevated and linked to fatigue in relapsing-remitting multiple sclerosis, even without heat exposure.
    Sumowski JF; Leavitt VM
    Arch Phys Med Rehabil; 2014 Jul; 95(7):1298-302. PubMed ID: 24561056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of acupuncture for fatigue in patients with relapsing-remitting multiple sclerosis: a randomized controlled trial.
    Khodaie F; Naser Moghadasi A; Kazemi AH; Zhao B
    Acupunct Med; 2023 Aug; 41(4):199-205. PubMed ID: 36722418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
    Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
    Schwartzbach CJ; Grove RA; Brown R; Tompson D; Then Bergh F; Arnold DL
    J Neurol; 2017 Feb; 264(2):304-315. PubMed ID: 27888416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind pilot study of the effect of Prokarin on fatigue in multiple sclerosis.
    Gillson G; Richard TL; Smith RB; Wright JV
    Mult Scler; 2002 Feb; 8(1):30-5. PubMed ID: 11936486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.